KRAS G12C–Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27146455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Daniel Rosas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Cancer Institute, Hematology Oncology Fellowship, Hollywood, FL 33021, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
KRAS G12C, long considered an undruggable oncogenic driver, has become one of the most consequential therapeutic targets in non-small cell lung cancer (NSCLC). The discovery of a cryptic binding pocket accessible in the GDP-bound state enabled covalent inhibitors—sotorasib and adagrasib—that have received regulatory approval for previously treated KRAS G12C-mutant NSCLC, with sotorasib demonstrating PFS and OS superiority over docetaxel in CodeBreaK 200 and adagrasib showing meaningful intracranial activity and a progression-free survival benefit over docetaxel in KRYSTAL-12. Yet response durability is limited by on-target switch-II pocket mutations, upstream RTK and SHP2-mediated bypass signaling, downstream MAPK and PI3K-AKT reactivation, phenotypic plasticity, and adverse modulation by co-occurring STK11, KEAP1, and TP53 alterations. Next-generation covalent inhibitors (divarasib, glecirasib, olomorasib), tri-complex RAS(ON) inhibitors (RMC-6291), pan-KRAS agents, and rationally designed combinations with EGFR, SHP2, SOS1, and PD-1 inhibitors are repositioning KRAS-directed therapy toward earlier lines of treatment. This review integrates the structural, signaling, and clinical biology of KRAS G12C with contemporary trial and real-world evidence to examine the emerging case for first-line KRAS G12C inhibition in genomically defined subsets of NSCLC. First-line use nonetheless remains investigational; platinum-based chemoimmunotherapy remains the standard of care outside of clinical trials, and a frontline indication will require confirmation from randomized phase III trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Cancer Institute, Hematology Oncology Fellowship, Hollywood, FL 33021, USA.
- Harnett Health Internal Medicine Residency, Dunn, NC 28334, USA.
ORCID-Profile: Daniel Rosas, Priyanka Barad, Luis Raez
Zitieren
APA
Rosas, D., Barad, P., Wright, J., & Raez, L. (2026). KRAS G12C–Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146455
Vancouver
Rosas D, Barad P, Wright J, Raez L. KRAS G12C–Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27146455
BibTeX
@article{Rosas2026,
author = {Rosas, Daniel and Barad, Priyanka and Wright, Jervon and Raez, Luis},
title = {KRAS G12C–Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27146455}
}
EUVIMED